
    
      An open-label, single-arm, multi-centre phase II trial for patients with refractory multiple
      myeloma and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors
      Encorafenib (LGX818 in) combination with Binimetinib (MEK162). The patients must have
      received at least two prior therapy regimen (at least one immunomodulatory drug and one
      proteasome inhibitor).

      The subjects receive LGX 818 450 mg. p.o. once daily and MEK 162 45 mg p.o. twice daily until
      disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as
      28 days.
    
  